|Bid||54.40 x 800|
|Ask||54.45 x 1000|
|Day's Range||52.95 - 56.05|
|52 Week Range||33.30 - 59.05|
|PE Ratio (TTM)||39.51|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT). The S&P 500 Growth index generated a three-year and five-year annualized return of 13.2% and 15.2%, respectively. These returns compare to the S&P 500 (SPY) at 10.7% and 13% for the same timespan, respectively. The S&P 500 Growth index generated YTD (year-to-date) return of 5.5%, compared to the S&P 500 at 1.5%. The S&P 500 Growth has 41% exposure to information technology, compared to the S&P 500 at 24.8%. ...
Leading biotech stock and IBD 50 member Ligand Pharmaceuticals is in a buy zone after reporting 172% earnings growth.
The biotech group is trying to climb past its 50-day moving average, so it may be a good time to keep an eye on biotech ETFs.
On a per-share basis, the Rockville, Maryland-based company said it had net income of 49 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding SUPN totaled $776 million.
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
Supernus Pharmaceuticals (SUPN) stock has risen 18.2%, from $38.75 on March 1, 2018, to $45.80 on March 29, 2018. In its 2017 results announced on February 28, 2018, the company focused on developing and commercializing drugs targeted at treating central nervous system diseases. It reported a 41% year-over-year (or YoY) growth in fiscal 2017 revenues, which were about $300 million. It also reported earnings before income tax of around $100 million in 2017, which is a YoY rise of 100%. ...
Now we know Maryland is helping out to the tune of more than $1.7 million. Maryland Gov. Larry Hogan announced Wednesday the state will provide $800,000 loan through the Maryland Economic Development Assistance Authority and Fund to assist with the move. Montgomery County is providing a $500,000 conditional grant through its Economic Development Fund, and Gaithersburg is providing a grant up to $400,000 through its Economic Development Opportunity Fund.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
After a year of surging growth, Supernus Pharmaceuticals Inc. is building out a new home double its current size. The Rockville biotech, which specializes in creating therapies for central nervous system diseases, is moving its headquarters to the Firstfield Life Science Cluster at 700 Quince Orchard Road in Gaithersburg, leasing approximately 119,000 square feet, according to a filing with the Securities and Exchange Commission. It's nearly 8 miles north on Interstate 270 from its current digs, at 1550 E. Gude Drive, where it occupies 44,500 square feet of laboratory and office space.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
On a per-share basis, the Rockville, Maryland-based company said it had profit of 26 cents. Earnings, adjusted for pretax expenses, came to 44 cents per share. The results beat Wall Street expectations. ...
On Tuesday, Supernus Pharmaceuticals (NASDAQ: SUPN ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Supernus Pharmaceuticals EPS will likely ...
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $664 million over the last one-month into ETFs that hold SUPN are among the lowest of the last year and appear to be slowing.
Several D.C.-area publicly traded companies saw their stock prices hit in recent days as U.S. stock exchanges saw a widespread selloff Friday, continuing into Monday trading. In the worst stock market ...